购物车
- 全部删除
- 您的购物车当前为空
(Rac)-JBJ-04-125-02 (JBJ-04-125-02) 是 JBJ-04-125-02 的消旋体,是选择性突变,可口服的 EGFR 变构抑制剂,对EGFRL858R/T790M 的IC50为 0.26 nM。
(Rac)-JBJ-04-125-02 (JBJ-04-125-02) 是 JBJ-04-125-02 的消旋体,是选择性突变,可口服的 EGFR 变构抑制剂,对EGFRL858R/T790M 的IC50为 0.26 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 847 | 现货 | |
5 mg | ¥ 2,280 | 现货 | |
10 mg | ¥ 3,660 | 现货 | |
25 mg | ¥ 5,890 | 现货 | |
50 mg | ¥ 8,190 | 现货 | |
100 mg | ¥ 10,800 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 2,730 | 现货 |
产品描述 | (Rac)-JBJ-04-125-02 (JBJ-04-125-02) is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer. |
靶点活性 | EGFR:0.26 nM |
体外活性 | (Rac)-JBJ-04-125-02为JBJ-04-125-02的外消旋体。JBJ-04-125-02是一种强效、突变选择性、变构位点特异性以及可口服的EGFR抑制剂,针对EGFRL858R/T790M的IC50为0.26 nM[1]。 |
体内活性 | Osimertinib与JBJ-04-125-02的组合,比单独使用任何一种化合物都是一种效果显著更佳的治疗方法[1]。 |
动物实验 | Ba/F3, H1975, H3255GR and H3255DR cells were treated with increasing concentrations of inhibitors for 72 hours and growth or the inhibition of growth was assessed by MTS assay according to previously established methods. |
别名 | JBJ-04-125-02 |
分子量 | 543.61 |
分子式 | C29H26FN5O3S |
CAS No. | 2140807-05-0 |
Smiles | Oc1ccc(F)cc1C(N1Cc2ccc(cc2C1=O)-c1ccc(cc1)N1CCNCC1)C(=O)Nc1nccs1 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 55 mg/mL (101.17 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容